Business Context and Reporting Period
Company: BioTime, Inc. (Note: Input metadata referenced "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.)
Reporting Period: Fiscal year ended December 31, 2003
Status: Development stage company engaged in the research and development of synthetic plasma volume expanders, blood replacement solutions, and organ preservation solutions.
Key Product: Hextend®, a blood plasma volume expander licensed exclusively to Abbott Laboratories for the U.S. and Canada. Other products in development include PentaLyte® and HetaCool®.
Key Financial Metrics
| Metric | 2003 | 2002 |
|---|---|---|
| Total Revenue | $556,422 | $387,020 |
| Net Loss | $(1,742,074) | $(2,844,932) |
| Loss Per Share (Basic & Diluted) | $(0.12) | $(0.22) |
| Cash and Cash Equivalents (Year End) | $717,184 | $1,284,432 |
| Working Capital | $(2,087,234) | $883,695 |
| Research & Development Expenses | $903,018 | $1,103,490 |
| General & Administrative Expenses | $1,260,712 | $1,318,159 |
| Accumulated Deficit (Inception to 2003) | $(35,382,075) | $(33,640,001) |
Note: The company had no long-term debt as of December 31, 2003, as debentures were classified as current liabilities due to maturity in August 2004. These were subsequently retired in February 2004.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 44% to $556,422, driven primarily by a 46% increase in royalty revenue from Abbott Laboratories ($514,235 vs. $352,641) and the recognition of $42,187 in license fees from a new agreement with CJ Corp. for South Korea.
- Reduced Net Loss: Net loss decreased by approximately 39% to $1.74 million, aided by a $1.0 million non-recurring gain from a key man life insurance policy following the death of the Chairman and CEO in June 2003.
- Expense Reduction: R&D expenses decreased by $200,472 due to reduced salaries and insurance costs. G&A expenses decreased slightly by $57,447.
- Liquidity Position: Cash on hand decreased by $567,248 to $717,184. Working capital turned negative due to the classification of $2.69 million in debentures as a current liability.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Resources: Management estimates cash on hand, combined with anticipated royalties and license fees, will last approximately 18 months from the filing date. The company raised $3.58 million in a rights offering in January 2004 and used proceeds to retire $3.35 million in debenture debt in February 2004, resulting in positive working capital post-filing.
- Product Development:
- Hextend: Sales are in the ramp-up phase. Abbott is awaiting Canadian government reimbursement authorization for a Q2 2004 launch.
- PentaLyte: Phase I clinical trials completed. Phase II trials are planned but dependent on capital availability (estimated cost $1 million).
- HetaCool: Development continues for low-temperature surgery and organ preservation; clinical trial costs are not yet determinable.
- Key Risks:
- Delisting Risk: The company is not in compliance with American Stock Exchange (AMEX) continued listing standards regarding shareholder equity and profitability. An extension was granted until April 2005 to regain compliance, likely requiring additional equity capital.
- Regulatory Approval: Future revenues depend on FDA and foreign regulatory approvals for PentaLyte and HetaCool.
- Competition: Faces competition from established plasma expanders (e.g., albumin, crystalloids) and generic hetastarch solutions.
- Management Transition: Following the death of CEO Paul Segall, executive duties are shared by an "Office of the President" comprising three founders. A new CEO has not been appointed to avoid additional compensation costs.
Investor Verification Checklist
- Capital Adequacy: Verify the sufficiency of the $3.58 million raised in January 2004 to fund the planned 18-month runway and the $1 million PentaLyte Phase II trial.
- Listing Status: Monitor progress toward meeting AMEX listing standards (positive equity of $4 million or market cap of $50 million) by the April 2005 deadline to avoid delisting.
- Abbott Sales Data: Confirm the trajectory of Hextend sales and royalty payments from Abbott, as this is the primary revenue source.
- Regulatory Milestones: Track the status of Canadian reimbursement for Hextend and FDA requirements for PentaLyte Phase II/III trials.
- Debt Retirement: Confirm the full extinguishment of the $3.35 million debenture debt via the February 2004 cash repayment and stock conversion.